IVERIC bio, Inc.
- Jurisdiction
United States - LEI
549300GZXI59U71XPM70 - ISIN
US46583P1021 (ISEE )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
1
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
3
/ 7
Profile
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). Read full profile
Stock price
Fundamentals
- Net revenue
€0.00 - Gross margin
0.0% - EBIT
-€197.60M - EBIT margin
0.0% - Net income
-€190.05M - Net margin
0.0%
Statement period: - (published )
Dividends
No dividend payouts
Earnings Calls
Latest earnings call: March 1, 2023